CytomX Therapeutics CTMX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- CytomX Therapeutics (CTMX) reported comprehensive income (loss), net of tax, attributable to parent of -$18.26M in Q1 2026.
- How has CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 177.7% year-over-year, from $23.5M to -$18.26M.
- What is the long-term trend for CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2021 to 2025), CytomX Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -47.0% compound annual growth rate (CAGR), from -$116.06M to -$17.28M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a broader view of financial performance by incorporating unrealized gains or losses that are excluded from the traditional net income statement. This metric is essential for assessing the total impact of market and operational factors on the company's overall equity position.